{"id":7161,"date":"2025-05-29T10:25:12","date_gmt":"2025-05-29T07:25:12","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7161"},"modified":"2025-05-29T10:25:12","modified_gmt":"2025-05-29T07:25:12","slug":"tezepelumab-shows-promise-in-severe-nasal-polyposis-and-asthma-reduces-surgery-steroid-use-and-inflammation","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/tezepelumab-shows-promise-in-severe-nasal-polyposis-and-asthma-reduces-surgery-steroid-use-and-inflammation\/","title":{"rendered":"Tezepelumab Shows Promise in Severe Nasal Polyposis and Asthma: Reduces Surgery, Steroid Use, and Inflammation"},"content":{"rendered":"
Tezepelumab Shows Promise in Severe Nasal Polyposis and Asthma: Reduces Surgery, Steroid Use, and Inflammation.<\/div>\n
Source: Medscape Medical News<\/div>\n
& published in The New England Journal of Medicine and presented at the 2025 AAAAI\/WAO annual meeting.<\/div>\n
Date: May 15, 2025<\/div>\n
<\/div>\n
1. Study Overview:<\/span><\/div>\n
\u2022 The phase 3 WAYPOINT trial evaluated tezepelumab (Tezspire) in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP).<\/span><\/div>\n
2. Mechanism of Action:<\/span><\/div>\n
\u2022 Tezepelumab is a first-in-class monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a key upstream cytokine in airway inflammation.<\/span><\/div>\n
\u2022 Developed by AstraZeneca and Amgen.<\/span><\/div>\n
3. Trial Design:<\/span><\/div>\n
\u2022 Randomized, double-blind, placebo-controlled, multicenter trial.<\/span><\/div>\n
\u2022 Patients received tezepelumab or placebo for 52 weeks, with a follow-up period of 12\u201324 weeks.<\/span><\/div>\n
4. Primary Outcomes:<\/span><\/div>\n
\u2022 Significant reduction in nasal polyp (NP) severity by \u22122.065 points (P < .0001).<\/span><\/div>\n
\u2022 88% reduction in systemic corticosteroid use (P < .0001).<\/span><\/div>\n
\u2022 Improvements began as early as week 2 (nasal congestion) and week 4 (NP score), sustained through week 52.<\/span><\/div>\n
5. Secondary Outcomes:<\/span><\/div>\n
\u2022 98% reduction in need for nasal polyp surgery (P < .0001).<\/span><\/div>\n
\u2022 Continued 88% corticosteroid use reduction.<\/span><\/div>\n
\u2022 Improved SNOT-22 scores and olfactory function.<\/span><\/div>\n
6. Expert Commentary:<\/span><\/div>\n
\u2022 Dr. Geoffrey Mortuaire (Lille University Hospital, France) stated tezepelumab shows potential to reduce surgeries and systemic steroid use, with rapid, sustained clinical response.<\/span><\/div>\n
7. Safety Profile:<\/span><\/div>\n
\u2022 Generally well tolerated, with a safety profile similar to its use in asthma.<\/span><\/div>\n
\u2022 Common adverse events: COVID-19, nasopharyngitis, and upper respiratory infections.<\/span><\/div>\n
\u2022 No significant safety differences between treatment and placebo groups.<\/span><\/div>\n
8. Current Approval & Future Outlook:<\/span><\/div>\n
\u2022 Already approved for severe asthma in over 60 countries.<\/span><\/div>\n
\u2022 Regulatory applications for severe nasal polyposis under review in multiple regions.<\/span><\/div>\n
9. Approved Use in Severe Asthma:<\/span><\/div>\n
\u2022 Tezepelumab is approved as an add-on maintenance therapy for severe asthma in adults and adolescents aged 12 years and older.<\/span><\/div>\n
\u2022 It is indicated for patients who remain uncontrolled despite high-dose inhaled corticosteroids and additional maintenance therapies.<\/span><\/div>\n
\u2022 The drug has demonstrated efficacy in reducing asthma exacerbations, improving lung function, and decreasing eosinophilic inflammation \u2014 regardless of baseline eosinophil count.<\/span><\/div>\n
\u2022 It is approved in the United States, Europe, Japan, and more than 60 countries worldwide.<\/span><\/div>\n
https:\/\/click.mail.medscape.com\/?qs=ac09fb0e85f8424e9bb4d0a894d1aef7c6eede28111fc5d859f85c80da9b9776f5b9f790a7273959a2bbd4dc857a1194b7d52baa95db6f38<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Tezepelumab Shows Promise in Severe Nasal Polyposis and Asthma: Reduces Surgery, Steroid Use, and Inflammation. Source: Medscape Medical News & published in The New England Journal of Medicine and presented at the 2025 AAAAI\/WAO annual meeting. Date: May 15, 2025 1. Study Overview: \u2022 The phase 3 WAYPOINT trial evaluated tezepelumab (Tezspire) in adults with […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7161","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7161"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7161\/revisions"}],"predecessor-version":[{"id":7162,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7161\/revisions\/7162"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}